Lamisil Once (Terbinafine)

Terbinafine belongs to the allylamine class of antifungals. It blocks the fungal enzyme squalene epoxidase, which is required for the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting ergosterol production, terbinafine causes toxic buildup of squalene and leads to fungal cell death.

The specific dose and frequency of Lamisil Once are determined by the prescribing healthcare professional based on the infection’s location, severity and patient factors. Patients should follow the prescriber’s instructions and the product label for proper application.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil Once.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lamisil Once. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil Once (topical terbinafine) offers a targeted approach for dermatophyte skin infections with a mechanism that differs from azole antifungals, which inhibit a later step in ergosterol synthesis. Terbinafine often requires shorter treatment durations and may be effective against strains resistant to azoles, but choice of therapy should be guided by clinical assessment.

Lamisil Once should be stored at room temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Apply a thin layer of Lamisil Once to the affected skin area once daily, or as directed by a healthcare professional. Gently rub the medication into clean, dry skin, and wash your hands after application unless the hands are being treated.

While uncommon, serious adverse reactions can include severe allergic responses such as angioedema, anaphylaxis, or rare skin conditions like Stevens‑Johnson syndrome. If you experience swelling, difficulty breathing, widespread rash, or blistering, discontinue use immediately and seek medical attention.

Lamisil Once should not be used on broken, inflamed or infected skin without medical advice, nor on mucous membranes such as the eyes, mouth or genital area. Individuals with known hypersensitivity to terbinafine or any component of the formulation should avoid using this product.